Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could regular MRIs replace invasive biopsies for prostate cancer monitoring?

NCT ID NCT06280781

Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares regular MRI scans to standard care for men with low- to medium-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). The goal is to see if MRIs can detect cancer progression earlier and more accurately, potentially reducing the number of biopsies and other tests. Over 1,200 participants will be followed for 5 years to measure cancer progression rates and cost-effectiveness for the NHS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scans
What this could lead to
If successful, regular MRI scans could become the new standard for monitoring low- to medium-risk prostate cancer, catching progression earlier and reducing the need for invasive biopsies.
What could go wrong
This is a large trial but still ongoing, and results may show that regular MRIs don't significantly improve detection or are not cost-effective for the NHS. MRI also has limitations and may miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,263 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or above (no upper limit) * Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all). * Diagnostic bi-parametric or multiparametric MRI * Diagnostic systematic biopsy +/- targeted biopsy * A histological diagnosis of localised prostate cancer * Patient chosen active surveillance Exclusion Criteria: * On active surveillance for greater than 9 months prior to screening date. * Contraindication to MRI or gadolinium contrast * Previous hip replacement to both hips * Contraindication to performing a biopsy guided by a transrectal ultrasound probe

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bradford Royal Infirmary

    RECRUITING

    Bradford, United Kingdom

  • Charing Cross Hospital

    RECRUITING

    London, W6 8RF, United Kingdom

  • Darent Valley Hospital

    RECRUITING

    Dartford, Kent, DA2 8DA, United Kingdom

  • Freeman Hospital

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Glan Clywd Hospital

    RECRUITING

    Rhyl, United Kingdom

  • Heatherwood Hospital

    RECRUITING

    Ascot, Berkshire, SL5 7GB, United Kingdom

  • Kings College London

    RECRUITING

    London, United Kingdom

  • North Cumbria

    RECRUITING

    Whitehaven, United Kingdom

  • Northern Lincolnshire and Goole NHS Foundation Trust

    RECRUITING

    Scunthorpe, United Kingdom

  • Southampton University Hospital

    RECRUITING

    Southampton, United Kingdom

  • St Peter's Hospital

    RECRUITING

    Chertsey, United Kingdom

  • West Middlesex Hospital

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.